ArticleJournal of thrombosis and thrombolysis2026
Admission serum mitochondrial DNA relative abundance is associated with angiographic no-reflow or slow-flow after primary percutaneous coronary intervention in STEMI.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thrombosis: focus on molecular mechanisms, biomarkers and cardio-oncology.Journal of thrombosis and thrombolysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to evaluate the independent association of admission serum mitochondrial DNA (mtDNA) relative abundance with no‑reflow or slow‑flow (NR/SF) after primary percutaneous coronary intervention (PPCI) in patients with acute ST‑segment elevation myocardial infarction (STEMI), and to quantify its incremental predictive value along the clinical timeline. We prospectively enrolled 892 consecutive STEMI patients undergoing PPCI and measured pre‑procedural serum mtDNA relative abundance using quantitative real‑time polymerase chain reaction (qPCR). After overlap weighting adjustment for 17 baseline covariates, high mtDNA abundance was independently associated with an increased risk of NR/SF (OR = 2.461, 95% CI 1.535-3.948, P < 0.001), with an absolute risk difference of 11.73%, and the exposure-response relationship exhibited a significant non‑linear threshold pattern (non‑linear P = 0.006). This association remained significant for both the NR component (OR = 2.689, 95% CI 1.377-5.250, P = 0.004) and the SF component (OR = 1.940, 95% CI 1.044-3.604, P = 0.036), and high mtDNA levels were also associated with higher in‑hospital risks of cardiogenic shock, acute heart failure, and severe arrhythmias. In predictive modeling, adding mtDNA to the early admission baseline model significantly improved the area under the curve (AUC) from 0.616 to 0.680 (ΔAUC = 0.064, DeLong P = 0.001), with a net reclassification improvement index of 0.453 and an integrated discrimination improvement index of 0.035. However, once angiographic or periprocedural characteristics were introduced, the incremental predictive value no longer reached statistical significance (ΔAUC = 0.023, P = 0.056-0.068). In conclusion, elevated admission serum mtDNA relative abundance is independently associated with post‑PPCI angiographic NR/SF in STEMI patients, showing a threshold‑like exposure-response relationship; its incremental predictive value is confined to the pre‑angiographic phase, suggesting that it may serve as an auxiliary biomarker for pre‑procedural risk stratification rather than an independent predictive tool.
Indexed as
Identifiers
42859329What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.